Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Rating

Rating methodology
Latest close (chg%)1078.78+1.37%
Buy price
1080.00
Target price1250.00
Sell price962.00
P/E TTM36.01
P/E91.43
Confidence70%
Risk score65/100
AI Summary
The committee recommends a Buy based on explosive growth momentum (55% revenue, 168% net income), strategic pivot to a broad-based biopharma innovator via the Ascidian deal, and bullish technical alignment. This is executed within a strict risk-aware framework that acknowledges extreme valuation (P/E 91) and high leverage (Debt/Assets 73%) as key risks.

Alpha Score

0-10
  • Trend（Score 6/10）

    The technical picture for Eli Lilly and Company (LLY) is bullish, with a clear uptrend supported by multiple indicators, though short-term volatility and consolidation are likely.

  • Valuation（Score 2/10）

    The stock's valuation is at premium levels, reflecting its hyper-growth status and market leadership. Valuation metrics (P/E, P/B, P/S) are at historically high levels, indicating the stock is fully valued to overvalued on a traditional basis.

  • Financial strength（Score 6/10）
    The company's financial health shows a mixed but generally robust picture, with strong liquidity and profitability metrics, but notably high financial leverage which increases risk.
  • Profitability（Score 10/10）
    Eli Lilly and Company is demonstrating extraordinary and accelerating profitability growth, with explosive revenue and earnings growth coupled with significant margin expansion.
  • Sentiment（Score 9/10）
    Eli Lilly's recent strategic expansion into gene therapy, positive clinical data, and strong financial performance create a compelling bullish case supporting both short-term price momentum and enhanced long-term value.
Latest price
$1078.78+1.37%
Market cap1.02T
P/E TTM36.01
P/E91.43
Volume2.65M
Turnover2.83B